BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15916799)

  • 1. Temozolomide in uterine leiomyosarcomas.
    Anderson S; Aghajanian C
    Gynecol Oncol; 2005 Jul; 98(1):99-103. PubMed ID: 15916799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma.
    Talbot SM; Keohan ML; Hesdorffer M; Orrico R; Bagiella E; Troxel AB; Taub RN
    Cancer; 2003 Nov; 98(9):1942-6. PubMed ID: 14584078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series.
    Ferriss JS; Atkins KA; Lachance JA; Modesitt SC; Jazaeri AA
    Int J Gynecol Cancer; 2010 Jan; 20(1):120-5. PubMed ID: 20130512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; SouliƩ P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
    Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
    Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
    Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
    Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma.
    Yeh KH; Lu YS; Hsiao CH; Cheng AL
    Anticancer Res; 2003; 23(6D):5133-7. PubMed ID: 14986591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
    Traina TA; Sabbatini P; Aghajanian C; Dupont J
    Gynecol Oncol; 2004 Oct; 95(1):235-41. PubMed ID: 15385138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.
    Edmonson JH; Marks RS; Buckner JC; Mahoney MR
    Cancer Invest; 2002; 20(5-6):605-12. PubMed ID: 12197215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
    Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
    Harris MT; Rosenthal MA; Ashley DL; Cher L
    J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete remission of recurrent and refractory uterine epithelioid leiomyosarcoma using weekly administration of bevacizumab and temozolomide.
    Takano M; Kikuchi Y; Susumu N; Kudoh K; Kita T; Kouta H; Goto T; Furuya K
    Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):236-8. PubMed ID: 21440979
    [No Abstract]   [Full Text] [Related]  

  • 15. Temozolomide in the treatment of recurrent malignant glioma.
    Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
    Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Rose PG; Blessing JA; Soper JT; Barter JF
    Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study.
    Long HJ; Blessing JA; Sorosky J
    Gynecol Oncol; 2005 Nov; 99(2):339-42. PubMed ID: 16051328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I trial of protracted oral fixed-dose temozolomide.
    Jones SF; Greco FA; Gian VG; Miranda FT; Raefsky EL; Hainsworth JD; Willcutt NT; Beschorner AF; Kennerly G; Burris HA
    Cancer; 2005 Nov; 104(9):1985-91. PubMed ID: 16134182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
    Tavella K; Villanucci A; Vannini L; Lavacchi D; Montelatici S; Amunni G; Mazzei T
    Anticancer Drugs; 2017 Apr; 28(4):465-468. PubMed ID: 28181940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.